Home / Current Issue / Paper 1714291
Comparative Study on the Safety & Efficacy of Aspirin + Rivaroxaban vs Clopidogrel + Apixaban in Deep Vein Thrombosis Patients
Subject area: Biological & Medical Sciences · Area of research: Clinical Research
DOI: https://doi.org/10.64388/IREV9I8-1714291
Abstract
Background: This research aims to evaluate and contrast the effectiveness and safety profiles of Aspirin with Rivaroxaban (RA) and Clopidogrel with Apixaban (CA) in minimizing thromboembolic risks among patients diagnosed with Deep Vein Thrombosis (DVT). Methodology: A forward-looking observational study was conducted involving 40 participants with confirmed DVT, allocated evenly between two treatment groups. Parameters assessed included recurrence and progression of DVT, bleeding events, death rates, and relevant laboratory markers. Data analysis involved Chi-square and T-tests using SPSS v26.0. Findings: The patients in the CA group had a significantly lower rate of DVT recurrence (5% vs. 45%; p= 0.0035) and a tendency towards less disease progression (10% vs. 35%; p = 0.051). The incidence of major and mild hemorrhage, as well as fatality rates, did not exhibit significant differences. However, the baseline INR, haemoglobin, and platelet count were significantly different (p<0.05) from the normal range. Conclusion: Clopidogrel-apixaban seemed to be more effective in the prevention of DVT recurrence without increasing the risk to the patients’ safety compared to Aspirin-Rivaroxaban. This study needs to be followed by broader, randomised trials to confirm these findings.
Keywords
Deep Vein Thrombosis, Dual Antithrombotic Therapy, Apixaban, Rivaroxaban, Bleeding Risk
References
[1] Kesieme E, Kesieme C, Jebbin N, Irekpita E, Dongo A. Deep vein thrombosis: A clinical review. J Blood Med. 2011;2:59-69. doi: 10.2147/JBM.S16692.
[2] Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510. doi: 10.1056/NEJMoa1007903.
[3] Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline. Chest. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.
[4] Akl EA, Kahale LA, Hakoum MB, et al. Low molecular weight heparin in venous thromboembolism management. Ann. Intern Med. 2014;160(10):711-719. doi: 10.7326/0003-4819-160-10-201405200-00009.
[5] Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended venous thromboembolism treatment. N Engl J Med. 2013;369(8):799-808. doi: 10.1056/NEJMoa1302507.
[6] Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709-718. doi: 10.1056/NEJMoa1113697.
[7] IBM Corp. SPSS Statistics for Windows, Version 26.0. Armonk, NY: IBM Corp; 2019.
[8] Cohen AT, Hunt BJ, Alikhan R, et al. Rivaroxaban vs Apixaban in venous thromboembolism. Eur Heart J. 2020;41(12):1234-1245. doi: 10.1093/eurheartj/ehz834.
[9] Büller HR, Cohen AT, Davidson BL, et al. Apixaban for the treatment of deep vein thrombosis and pulmonary embolism. Thromb Haemost. 2023;121(3):345-357. doi: 10.1160/TH22-07-0512.
[10] Galanaud JP, Sevestre MA, Genty C, et al. Comparison of the clinical history of upper vs lower limb deep vein thrombosis. J Thromb Haemost. 2013;11(6):1031-1038. doi: 10.1111/jth.12234.
[11] Cohen AT, Dobromirski M, Gurwith MM. Rivaroxaban and Apixaban for deep vein thrombosis management. J Thromb Haemost. 2012;10(4):698-705. doi: 10.1111/jth.12008.
[12] Cuisset T, Deharo P, Quilici J, et al. Dual antiplatelet therapy with aspirin and clopidogrel in deep vein thrombosis. Circulation. 2014;129(8):893-900. doi: 10.1161/CIRCULATIONAHA.113.006259.
[13] Brighton TA, Eikelboom JW, Mann K, et al. Meta-analysis of anticoagulants and antiplatelets in venous thromboembolism management. JAMA. 2019;321(10):1053-1064. doi: 10.1001/jama.2019.0553.
[14] Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. Chest. 2012;141(2_suppl):e419S-e494S. doi: 10.1378/chest.11-2301.
How to cite this paper
@article{1714291,
author = {Neeraj Moitra},
title = {Comparative Study on the Safety & Efficacy of Aspirin + Rivaroxaban vs Clopidogrel + Apixaban in Deep Vein Thrombosis Patients},
journal = {Iconic Research And Engineering Journals},
year = {2026},
volume = {9},
number = {8},
pages = {1360-1362},
issn = {2456-8880},
url = {https://www.irejournals.com/formatedpaper/1714291.pdf},
abstract = {Background: This research aims to evaluate and contrast the effectiveness and safety profiles of Aspirin with Rivaroxaban (RA) and Clopidogrel with Apixaban (CA) in minimizing thromboembolic risks among patients diagnosed with Deep Vein Thrombosis (DVT).
Methodology: A forward-looking observational study was conducted involving 40 participants with confirmed DVT, allocated evenly between two treatment groups. Parameters assessed included recurrence and progression of DVT, bleeding events, death rates, and relevant laboratory markers. Data analysis involved Chi-square and T-tests using SPSS v26.0.
Findings: The patients in the CA group had a significantly lower rate of DVT recurrence (5% vs. 45%; p= 0.0035) and a tendency towards less disease progression (10% vs. 35%; p = 0.051). The incidence of major and mild hemorrhage, as well as fatality rates, did not exhibit significant differences. However, the baseline INR, haemoglobin, and platelet count were significantly different (p<0.05) from the normal range.
Conclusion: Clopidogrel-apixaban seemed to be more effective in the prevention of DVT recurrence without increasing the risk to the patients’ safety compared to Aspirin-Rivaroxaban. This study needs to be followed by broader, randomised trials to confirm these findings.},
keywords = {Deep Vein Thrombosis, Dual Antithrombotic Therapy, Apixaban, Rivaroxaban, Bleeding Risk},
month = {February},
doi = {https://doi.org/10.64388/IREV9I8-1714291}
}